Results 21 to 30 of about 178,048 (244)

No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. [PDF]

PLoS ONE, 2013
Use of antiretroviral-based microbicides for HIV-1 prophylaxis could introduce a transmission barrier that inadvertently facilitates the selection of fitter viral variants among incident infections.
Denis R Chopera, Jaclyn K Mann, Philip Mwimanzi, Saleha Omarjee, Xiaomei T Kuang, Nonkululeko Ndabambi, Sarah Goodier, Eric Martin, Vivek Naranbhai, Salim Abdool Karim, Quarraisha Abdool Karim, Zabrina L Brumme, Thumbi Ndung'u, Carolyn Williamson, Mark A Brockman, CAPRISA 004 TRAPS Team   +15 more
doaj   +1 more source

Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance

, 2020
The HIV-1 protease is a major target of inhibitor drugs in AIDS therapies. The therapies are impaired by mutations of the HIV-1 protease that can lead to resistance to protease inhibitors.
Hemmateenejad, B., Weikl, T.
core   +1 more source

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom [PDF]

, 2001
Objectives: To identify changes since 1994 in the prevalence of resistance to anti-HIV drugs in primary HIV-1 infections in the United Kingdom. Design: Retrospective and prospective assessment of viruses obtained from people recently infected with HIV.
Baily, Guy, Cane, Patricia, Churchill, Duncan, Dean, Gill, Drake, Susan, Fisher, Martin, Pillay, Deenan, Porter, Kholoud   +7 more
core   +2 more sources

Prediction and molecular field view of drug resistance in HIV-1 protease mutants

Scientific Reports, 2022
Conquering the mutational drug resistance is a great challenge in anti-HIV drug development and therapy. Quantitatively predicting the mutational drug resistance in molecular level and elucidating the three dimensional structure-resistance relationships ...
Baifan Wang, Yinwu He, Xin Wen, Zhen Xi
doaj   +1 more source

In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1. [PDF]

, 2010
Although antiretroviral drug resistance is common in treated HIV infected individuals, it is not a consistent indicator of HIV morbidity and mortality.
Kitchen, Christina MR, Kitchen, Scott G, Krogstad, Paul   +2 more
core   +2 more sources

HIV-1 CRF 02 AG polymerase genes in Southern Ghana are mosaics of different 02 AG strains and the protease gene cannot infer subtypes

Virology Journal, 2009
Background Little is known about the detailed phylogeny relationships of CRF 02_AG HIV-1 polymerase genes in Ghana. The use of the protease gene of HIV-1 for subtyping has shown conflicting results. Methods The partial polymerase gene sequences of 25 HIV-
Sagoe Kwamena W, Dwidar Magda, Adiku Theophilus K, Arens Max Q   +3 more
doaj   +1 more source

Protease Cleavage Leads to Formation of Mature Trimer Interface in HIV-1 Capsid [PDF]

, 2012
During retrovirus particle maturation, the assembled Gag polyprotein is cleaved by the viral protease into matrix (MA), capsid (CA), and nucleocapsid (NC) proteins.
Angela M. Gronenborn, Christopher Aiken, Danxia Ke, Ernest Yufenyuy, Gongpu Zhao, Jinwoo Ahn, Jiying Ning, John A. T. Young, Maria DeLucia, Peijun Zhang, Xin Meng   +10 more
core   +4 more sources

Zero prevalence of primary drug resistance-associated mutations to protease inhibitors in HIV-1 drug-naive patients in and around Aligarh, India

Journal of Infection in Developing Countries, 2014
Introduction: This study aimed to evaluate the prevalence of resistance mutations in the protease gene of HIV-1 strains isolated from north Indian antiretroviral (ARV) treatment-naive patients and to assess the phylogenetic relatedness of these strains ...
Mohd Azam, Abida Malik, Meher Rizvi, Arvind Rai   +3 more
doaj   +1 more source

HIV-2 Protease resistance defined in yeast cells

Retrovirology, 2006
Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier, Audoly Gilles, M'Barek Najoua, Gluschankof Pablo   +3 more
doaj   +1 more source

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs [PDF]

, 2009
Background: The transmission of HIV-1 drug-resistant strains in drug naive patients may seriously compromise the efficacy of a first-line antiretroviral treatment.
A de Ronde, A Lindström, AM Wensing, AM Wensing, B Suligoi, B Suligoi, BA Payne, C Alteri, Carlo Federico Perno, Caterina Gori, Claudia Alteri, D Costagliola, D Pillay, D Posada, Department of Health and Human Services, Enrico Girardi, F Ceccherini-Silberstein, Francesca Ceccherini-Silberstein, HS Weinstock, J Vingerhoets, JD Thompson, JG Garcia-Lerma, KL Swafford, LT Bacheler, M Selleri, M Violin, Marina Selleri, Massimo Ciccozzi, Massimo Giuliani, ML Chaix, MM Santoro, MS Hirsch, N Orchi, Nicoletta Orchi, O Peuchant, Paola Elia, Paola Scognamiglio, RM Novak, Roberta Balzano, Roberta D'Arrigo, RW Shafer, RW Shafer, S Ray, S Yerly, SJ Little, SJ Little, SM Blower, SPREAD programme, Stefano Aviani Bardacci, T de Oliveira, TA Hall, UK Collaborative Group on HIV Drug-resistance, UK Collaborative HIV Cohort Study, UKRegister of HIV Seroconverters, V Svicher, V Tozzi, Valentina Svicher   +54 more
core   +2 more sources